Abstract：
Topical ruxolitinib, a potent Janus kinase (JAK) inhibitor, has shown significant efficacy in treating inflammatory skin conditions. While its use has already been established in atopic dermatitis and vitiligo, recent reports suggest its potential efficacy in treating other dermatoses. Specifically, topical ruxolitinib may be an effective treatment option for refractory dermatological conditions that are inflammation-driven with dysregulated activity of cytokines implicated in the JAK/STAT pathway. In this case series, we present four novel clinical applications of topical ruxolitinib in treatment-resistant dermatological conditions. These cases include pediatric lichen sclerosus et atrophicus, morphea, perioral dermatitis, and notalgia paresthetica. All four patients reported noticeable symptomatic improvement and a significant improvement in the condition of their skin lesions. Our results suggest that ruxolitinib cream can successfully manage these conditions and may serve as supporting evidence for its formal evaluation. J Drugs Dermatol. 2024;23(3): doi:10.36849/JDD.7696.
摘要：
外用鲁索利替尼，一种有效的Janus激酶（JAK）抑制剂，在治疗炎性皮肤病方面显示出显著的功效。虽然它的用途已经在特应性皮炎和白癜风中建立，最近的报道表明它在治疗其他皮肤病方面的潜在功效。具体来说,局部应用鲁索替尼可能是难治性皮肤病的有效治疗选择,这些疾病是由炎症驱动的,与JAK/STAT途径相关的细胞因子活性失调.在这个系列中,我们介绍了鲁索替尼在治疗耐药皮肤病中的四种新的临床应用。这些病例包括小儿硬化性苔藓和萎缩性苔藓，疣,口周皮炎,和感觉异常。所有四名患者均报告了明显的症状改善和皮肤病变状况的显着改善。我们的结果表明，鲁索利替尼乳膏可以成功地治疗这些疾病，并可以作为其正式评估的支持证据。J药物Dermatol。2024；23（3）：doi：10.36849/JD.7696。
